Approximately 20,000 patients will be diagnosed with chronic lymphocytic leukemia (CLL) in the United States alone in 2019. Many of these patients will be in the early-stage of their disease at the time of their diagnosis and will not meet indications for therapy (learn more about this period known as watch & wait).
It is now possible for Mayo Clinic hematologists to identify several prognostic markers to individually predict which patients are at a higher risk of progression. Learn more about the five variables providers use to determine who is at a higher risk in Dr. Parikh's video below: